Popular Articles
Stretch Mark Remedies

Picks For NIH Head, Surgeon General Side With Obama On Reproductive Issues, Despite Faith
Francis Collins, President Obama"s pick to head NIH, and Regina Benjamin, Obama"s surgeon general nominee, have spoken publicly about their religious beliefs but also have expressed views on issues such as embryonic stem cell research that conflict with church teachings, USA Today reports. Collins, who headed the Human Genome Project, is an evangelical Christian who supports the use of human embryonic stem cells in some medical research. Focus on the Family in a newsletter lauded Obama"s choice of an evangelical to lead NIH but said that abortion-rights opponents cannot support Collins" views, "particularly since he supports destructive human embryonic stem cell research."Benjamin is a Roman Catholic and sits on the board of the Catholic Health Association. She also is active in her local church and received a papal medal in 2006. According to USA Today, Catholic leaders from her native state of Alabama say they have not heard Benjamin voice support for abortion rights. The Bayou La Batre, La., medical clinic that she oversees does not perform abortions. Bill Donohue, president of the Catholic League, initially expressed support for Benjamin"s nomination, saying, "Her tireless and selfless efforts are a model for all physicians." He later said that he opposes any possible support she might give "mandated abortion coverage" in health reform.The White House has said that Benjamin agrees with Obama "on reproductive issues." Retired archbishop Oscar Lipscomb, who nominated Benjamin for the papal medal, said, "She is a practicing Catholic and faithful and, to the best of my knowledge, in all those questions that have arisen so far, there has never been a conflict in her practice and in her conversation with regard to what the church expects of medical practitioners." Former Surgeon General David Satcher, who taught Benjamin at Morehouse School of Medicine, said, "While the religion of the surgeon general may very well influence his or her ... approach, the message has to be the public health science," adding, "It"s not a religious message. It"s a public health science message."Emilie Townes, associate dean of academic affairs for Yale Divinity School, said that Obama"s choices represent his aim to "break the mold" of traditional politics, adding that Collins and Benjamin are examples of "big tent" evangelicalism and Catholicism (Banks, USA Today, 8/3).
generic viagra online
Inovio Biomedical To Present At International DNA Vaccine Conference
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that it will make multiple presentations at the Annual Conference of DNA Vaccines in Asia 2009 being hosted by the International Society of DNA Vaccines July 9 - 10 at the Beijing International Convention Center. The conference, with the theme, "Advancing DNA Vaccine Technology," is co-chaired by David B. Weiner, Ph.D., professor of pathology, University of Pennsylvania School of Medicine, and chairman of Inovio"s scientific advisory board.
News of the day
Washington Post Examines Lobbying Efforts Of Health Information Technology Industry
The Washington Post on Saturday examined the role of the Healthcare Information and Management Systems Society in lobbying for the national adoption of health information technology as part of health reform efforts. According to the Post, HIMSS has collaborated with various allies, including technology vendors and research groups, "in a sophisticated, decade-long campaign to shape public opinion and win over Washington"s political machinery."HIMSS in the early part of this decade forged a "strategic alliance" with the Center for Information Technology Leadership, a not-for-profit health IT research group in Massachusetts, to develop and distribute data reports on the cost efficiency and benefits of health IT, the Post reports. CITL also had sponsorship ties with several health and technology companies, including Google, Microsoft, Kaiser Permanente and Siemens Medical Solutions. In 2004, CITL issued a report that concluded in part that a national health IT system could reduce spending by as much as $77.8 billion by limiting drug prescribing errors and notifying providers of more cost-effective drug alternatives.According to the Post, the findings of the report were used by the Obama administration in developing the $787 billion federal economic stimulus package, which included billions in new spending for the creation and adoption of health IT systems. Although a Congressional Budget Office report found that the assumptions of CITL report were "overly optimistic" -- a follow-up CBO analysis projected that electronic health records would reduce health care spending by $17 billion over 10 years -- the health IT measures in the stimulus package "represented a triumph" for HIMSS, "whose members now stand to gain billions in taxpayer dollars," the Post reports. The Post notes that HIMSS" "sudden success shows how the economic crisis created a remarkable opening for a political and financial windfall: the enactment of a sweeping new policy with no bureaucratic delays and virtually no public debate about an initiative aimed at transforming a sector that accounts for more than a sixth of the American economy" (O"Harrow, Washington Post, 5/16).Please note: The Kaiser Family Foundation is not associated with Kaiser Permanente or Kaiser Industries.
Nutrition

FDA Accepts Final Section Of NDA Filing For LUCASSIN(R)

Orphan Therapeutics, LLC and Ikaria Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing seeking marketing approval for LUCASSIN(R) (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type 1. The filing was completed on May 4, 2009, and LUCASSIN has been granted Priority Review as well as Orphan Drug status and Fast Track designation. HRS Type 1 is the development of kidney failure in patients with late-stage liver cirrhosis in the absence of any other cause. It is characterized by rapid onset of renal failure with a high mortality rate that exceeds 80% within three months. In September 2008, Ikaria acquired the North American rights to LUCASSIN, including responsibility for manufacturing, distribution, marketing, sales, customer service and post-market development. Those rights will be transferred to Ikaria following marketing approval. LUCASSIN is a synthetic vasopressin analogue that acts via the vasopressin V1 receptor as a systemic vasoconstrictor, mainly in the splanchnic (abdominal) circulation, which appears to increase effective arterial volume and improves renal blood flow, thereby improving renal function in patients with HRS. Terlipressin was recently approved in France, Ireland, Spain and South Korea for the treatment of patients with HRS Type 1. Terlipressin is not approved by the FDA for use in the U.S. About Orphan Therapeutics, LLC Orphan Therapeutics, LLC, is a privately held drug development company dedicated to developing treatments for rare and serious diseases. It was founded in 2003 with the initial purpose to develop and seek U.S. FDA approval for its first product, LUCASSIN(R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) Type 1. About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company"s lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOmax is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Ikaria Holdings Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):